pharmaceuticals — Lanton Law Blog

Understanding the 2025 Executive Order on Most-Favored-Nation Drug Pricing: Implications for Healthcare Stakeholders

On May 12, 2025, President Trump signed an executive order titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," aiming to align U.S. prescription drug prices with the lowest prices paid by other developed nations.

Ron LantonMay 13, 2025Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients, Most-Favored-Nation (MFN) Pricing, Secretary of Commerce, U.S. Trade Representative, pharmaceuticals, tariffs, pharmaceutical tariffs

Section 232 Targets Drug Imports: What It Means for Pharma and Healthcare

On April 1, 2025, the U.S. Department of Commerce initiated a Section 232 national security investigation into the importation of pharmaceuticals and pharmaceutical ingredients. This inquiry aims to assess whether the reliance on foreign sources for essential medical products poses a threat to national security. The scope includes finished drug products, active pharmaceutical ingredients (APIs), key starting materials, and related derivatives.

drug distribution, healthcare, life sciences, pharmaceuticalsRon LantonApril 22, 2025Section 232, U.S. Department of Commerce, pharmaceuticals, supply chain, ingredients, active pharmaceutical ingredients

Pharmaceutical Commerce Speaks with Lanton Law about New Drug Pricing Models

Pharmaceutical Commerce interviews Ron Lanton; Partner at Lanton Law on newly emerging pricing models such as the cost plus drug model.

healthcare, legislation, life sciences, Congress, FTCRon LantonJanuary 31, 2024healthcare, drug price, Mark Cuban Cost Plus Drug Company, cost plus pricing model, Pharmacy Benefit Manager, insurance, pharmaceuticals, pharmacy, PhRMA

Biden Administration Announces First Ten Drugs Selected for Medicare Price Negotiation

The Biden Administration has announced today that Medicare will be able to negotiate drug prices for the first time due to provisions within the Inflation Reduction Act.

healthcare, life sciences, Medicare Part D, pharmaceuticals, prescription drug costsRon LantonAugust 29, 2023Inflation Reduction Act, drug prices, pharmaceuticals, prescription drug prices, Medicare Part D, CMS, HHS

White House Releases Report Outlining Steps to Strengthen Critical Supply Chains

In February 2021, President Biden issued an Executive Order to direct a government-wide “approach to assessing vulnerabilities in, and strengthening the resilience of, critical supply chains.”

semiconductor, manufacturing, supply chain, trade, telecommunications, technology, tech, pharmaceuticals, healthcareRon LantonJune 17, 2021Supply Chain, Executive Order, pharmaceuticals, active pharmaceutical ingredients, electric vehicles, semiconductor